LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Eli Lilly’s Omvoh ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Lily Allen, 40, sat down for an episode of her podcast, Miss Me?, where she revealed that she would "get pregnant all the time" and that she's had multiple abortions over the years.

LILLY — Winning pitcher P.J. Holberg scattered five hits in pitching Lilly Chiropractic to a 14-4 win over Refresh Med Spa in a Greater Altoona City League game Wednesday. Jake Hillard, Cody ...